Picture of GL Pharm Tech logo

204840 GL Pharm Tech Income Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for GL Pharm Tech, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue10,60811,98812,42616,72926,033
Cost of Revenue
Gross Profit2,0283,3113,7694,8778,709
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses15,87714,80115,39818,97228,749
Operating Profit-5,269-2,813-2,973-2,244-2,716
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-5,558-3,467-3,842-832-3,944
Provision for Income Taxes
Net Income After Taxes-5,515-3,356-3,734-790-3,749
Minority Interest
Net Income Before Extraordinary Items
Net Income-5,515-3,356-3,727-790-3,749
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income-5,515-3,356-3,727-790-3,749
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-115-73.5-69.4-41.3-65.6
Dividends per Share